tq-b3101
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2017 (NCT03019276)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
- ALK tyrosine kinase receptorINHIBITOR
ALK inhibitor
ROS1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tq-b3101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04804904 | Phase 1 | Mar 31, 2021 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT04412564 | Phase 2 | Jun 1, 2020 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT04306887 | Phase 2 | Nov 29, 2019 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT03972189 | Phase 2 | Jul 31, 2019 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT03019276 | Phase 1 | Feb 1, 2017 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 5 | 5 | 2 | 2017 |
1 organizations
Page 1 / 1